Anti-BTLA Antibodies Blocking HVEM for Stronger Immune Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for therapeutic antibodies that effectively inhibit or antagonize BTLA to treat diseases or conditions mediated through BTLA, such as cancer or infectious diseases, as existing treatments are inadequate in modulating immune responses effectively.
Innovation Solution
Development of isolated anti-BTLA antibodies with specific CDR sequences, including HC-CDR1, HC-CDR2, and HC-CDR3 for the heavy chain and LC-CDR1, LC-CDR2, and LC-CDR3 for the light chain, which bind potently to BTLA and inhibit its interaction with HVEM, enhancing immune activation and tumor immunity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing therapeutic antibodies are used to treat diseases mediated through BTLA, then treatment is provided, but immune response modulation is inadequate
Solution Approach 1:
The patent employs parameter changes by optimizing the antibody's binding affinity parameters through specific CDR sequence selection and engineering. The anti-BTLA antibodies are designed with enhanced binding characteristics (higher affinity and potency) compared to existing antibodies, directly addressing the inadequacy of immune response modulation while maintaining treatment effectiveness
2Reliability
If antibodies with high binding affinity to BTLA are developed, then immune activation is enhanced, but antibody design complexity increases
Solution Approach 1:
The patent applies segmentation by focusing optimization efforts on specific functional segments of the antibody - the Complementarity Determining Regions (CDRs). By identifying and optimizing the HC-CDR1, HC-CDR2, HC-CDR3, LC-CDR1, LC-CDR2, and LC-CDR3 sequences independently, the patent achieves high binding affinity without requiring complete redesign of the entire antibody structure, thus managing complexity while enhancing potency
Solution Approach 2:
The patent employs universality by designing antibody variants that maintain a common framework structure while allowing variability in CDR sequences. This approach enables multiple antibody variants with different binding affinities to be generated from a universal backbone, simplifying the design process while achieving the desired immune activation potency through CDR optimization
Data Source
AI summary
The present application provides antibodies including antigen binding fragments thereof that specifically recognize B- and T-lymphocyte attenuator (BTLA). Also provided are methods of making and using these antibodies